title: [The hepatorenal syndrome].
abstract: The hepatorenal syndrome is characterized by a combination of liver cirrhosis, ascites and renal impairment. It is divided into two typs, whereby typ I is defined as acute with a doubling of creatinine within 2 weeks and type II as a more modest decline of kidney function. The only definite therapy so far is transplantation. However, based on pathophysiological considerations a number of strategies have been applied. Aldosteronantagonists are the backbone of therapy even in cases of poor diuresis. Additional benefit is derived from a combination of vasopressors and albumine.
authors.affiliation: Abteilung für Nephrologie, Klinikum rechts der Isar, München.
authors.forename: Uwe
authors.initials: U
authors.lastname: Heemann
authors.affiliation: Praxis für Integrative Innere Medizin, München.
authors.forename: Hermann S
authors.initials: HS
authors.lastname: Füeßl
authors.affiliation: Abteilung für Nephrologie, Klinikum rechts der Isar, München.
authors.forename: Lutz
authors.initials: L
authors.lastname: Renders
mesh_terms: D006530:Hepatorenal Syndrome / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D017093:Liver Failure / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D016031:Liver Transplantation; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D014662:Vasoconstrictor Agents